A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer

PURPOSE: Rearranged ROS1 is a crizotinib-sensitive oncogenic driver in lung cancer. The development of acquired resistance, however, poses a serious clinical challenge. Consequently, experimental and clinical validation of resistance mechanisms and potential second-line therapies is essential. EXPER...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Drilon, Alexander, Somwar, Romel, Wagner, Jacob. P., Vellore, Nadeem. A., Eide, Christopher A., Zabriskie, Matthew. S., Arcila, Maria. E., Hechtman, Jaclyn F., Wang, Lu, Smith, Roger S., Kris, Mark. G., Riely, Gregory. J., Druker, Brian. J., O’Hare, Thomas, Ladanyi, Marc., Davare, Monika. A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4867287/
https://ncbi.nlm.nih.gov/pubmed/26673800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados